Bain Capital Life Sciences

• Talawar Therapeutics to Go Public via Business Combination with JATT II Acquisition Corp

  June 29, 2026

  Buyer

  JATT II Acquisition Corp, Access Biotechnology, Bain Capital Life Sciences, Deep Track Capital, RA Capital Management, Janus Henderson Investors, Vianti Capital, Farallon Capital Management, JATT Ventures II L.P.

  Target

  Talawar Therapeutics, Talawar Tx Inc

  Industry

  Biotechnology

  Location

  New Jersey, United States

  Type

  Buyout

  Talawar Therapeutics entered into a definitive business combination agreement with JATT II Acquisition Corp to create a publicly listed biotechnology company focused on developing bispecific antibodies for immunology and inflammatory diseases. The transaction is expected to close in the second half of 2026 and includes an oversubscribed $225 million PIPE alongside $60 million held in JATT II’s trust account (assuming no redemptions).

• Bain Capital and Bristol Myers Squibb Launch NewCo with $300M to Develop Immunology Therapies

  July 31, 2025

  Buyer

  Bain Capital, Canada Pension Plan Investment Board

  Target

  NewCo

  Seller

  Bristol Myers Squibb

  Industry

  Biotechnology

  Location

  United States

  Type

  Growth capital

  Bristol Myers Squibb (BMS) and Bain Capital have created a new independent biopharmaceutical company (NewCo) to advance five licensed immunology assets, with Bain Capital committing $300 million and support from the Canada Pension Plan Investment Board. BMS licensed three clinical-stage and two Phase 1-ready programs to NewCo and will retain nearly a 20% equity stake while joining the new company's board.

• Bain Capital Life Sciences Leads $200M Growth Investment in Serán Bioscience

  September 17, 2024

  Buyer

  Bain Capital Life Sciences, Vivo Capital

  Target

  Serán Bioscience

  Industry

  Pharmaceuticals

  Location

  Oregon, United States

  Type

  Growth capital

  Bain Capital Life Sciences led a strategic growth investment of more than $200 million in Serán Bioscience, with existing investor Vivo Capital remaining a key shareholder. The capital will fund a new commercial-scale manufacturing campus in Bend, Oregon, expanding Serán's development, analytical and commercial manufacturing capabilities across multiple drug delivery modalities.

• Century Therapeutics Acquires Clade Therapeutics; Raises $60M Private Placement Led by Bain Capital Life Sciences

  April 11, 2024

  Buyer

  Century Therapeutics, Bain Capital Life Sciences, Adage Capital Partners LP, Octagon Capital, Superstring Capital, Casdin Capital, Boxer Capital, Venrock Healthcare Capital Partners, DAFNA Capital Management, LLC

  Target

  Clade Therapeutics

  Industry

  Biotechnology

  Location

  Massachusetts, United States

  Type

  Buyout

  Century Therapeutics agreed to acquire privately held Clade Therapeutics for approximately $35 million in upfront consideration (plus a potential $10 million milestone) to expand its iPSC-derived cell therapy pipeline and next-generation Allo-EvasionTM platform. Concurrently, Century completed a roughly $60 million private placement led by Bain Capital Life Sciences and several institutional investors to support expanded autoimmune development of its lead program CNTY-101 and extend cash runway into 2026.

• Bain Capital Ventures and Insight Venture Partners Recapitalize SolarWinds.net

  September 1, 2023

  Buyer

  Bain Capital Ventures, Insight Venture Partners

  Target

  SolarWinds

  Industry

  Software

  Location

  Oklahoma, United States

  Type

  Recapitalization

  Bain Capital Ventures and Insight Venture Partners completed a recapitalization of SolarWinds.net, a privately held network management and systems software developer headquartered in Tulsa, Oklahoma. The equity transaction gave Bain and Insight a majority stake while preserving management and granting equity to key personnel to support continued growth and product expansion.

• Bain Capital Invests up to $300M in Cardurion Pharmaceuticals

  October 27, 2021

  Buyer

  Bain Capital Life Sciences, Bain Capital Private Equity

  Target

  Cardurion Pharmaceuticals

  Industry

  Biotechnology

  Location

  Massachusetts, United States

  Type

  Growth capital

  Cardurion Pharmaceuticals, a clinical‑stage biotechnology company focused on cardiovascular therapeutics, received a private investment of up to $300 million from Bain Capital Life Sciences and Bain Capital Private Equity to advance its PDE9 and CaMKII inhibitor programs and to scale the business. The funding will support a major Phase 2 heart‑failure trial, initiation of first‑in‑human studies, and company growth; Bain Capital will also join Cardurion’s board alongside existing investors Takeda Pharmaceuticals and Polaris Partners.

• Zelis and RedCard Complete Merger Backed by Parthenon and Bain Capital

  October 4, 2019

  Buyer

  Parthenon Capital, Bain Capital Private Equity, Bain Capital Ventures

  Target

  Zelis Healthcare, RedCard Systems

  Industry

  Healthcare Services

  Location

  United States

  Type

  Buyout

  Zelis Healthcare and RedCard Systems announced the completion of their merger to form a combined healthcare payments technology company serving payers and providers at enterprise scale. The transaction was supported by existing investor Parthenon Capital alongside Bain Capital Private Equity and Bain Capital Ventures; financial terms were not disclosed.

Related Acquisition Pages